looking more active, page-7

sirtex news gets the big clinical trials Since Sir Spheres are already known to work well synergistically with the newer chemo drugs in extending survival times by more than 100% in many cases these new trials just announced at close today and the ones already positively reported will put the FDA on fast track approval which is huge news for increasing the potential market potential for Sir Spheres which is in the billions and the market cap of Sirtex which is currently only 80 million USD. All the pharmas will scramble to get a piece of SRX but I have strong hunch that SRX is positioned by Dr Gray and Hunter hall already and aligned to sell the company by soliciting bids from the list of pharma companies I have mentioned. The 3 dysfunctional board members have no shares nor votes and will be ousted . Hunter hall is maintaining $7+++++ by holidays,and backing it up with continued buying. Due diligence by Cephalon lawyers 3 years ago when they bid $4.85 share confirms company is on solid ground . With conference this weekend in USA with more positive trial results the ball could start rolling very quickly and sp move up fast as float is small.Biospace still maintains company is already private


Sirtex Medical News from The BioSpace Beat

--------------------------------------------------------------------------------
Ownership: Private

--------------------------------------------------------------------------------


Sirtex Medical Supports The 2006 Carcinoid/Neuroendocrine Tumor Conference
LAKE FOREST, Ill.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, is a participating sponsor at this year’s Carcinoid/Neuroendocrine Tumor (NET) Conference. The conference, which is hosted by the Washington & Oregon Chapters of the Pacific Northwest Carcinoid Cancer Support Group, will be held September 28-30 at the DoubleTree Hotel’s Lloyd Center in Portland, Ore. The mission of the conference is to present the latest information on neuroendocrine tumors to patients, caregivers and physicians.
(See Story from BioSpace.com) (09/26/2006)



Sirtex Medical Supports The 2006 Carcinoid/Neuroendocrine Tumor Conference
LAKE FOREST, Ill.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, is a participating sponsor at this year’s Carcinoid/Neuroendocrine Tumor (NET) Conference. The conference, which is hosted by the Washington & Oregon Chapters of the Pacific Northwest Carcinoid Cancer Support Group, will be held September 28-30 at the DoubleTree Hotel’s Lloyd Center in Portland, Ore. The mission of the conference is to present the latest information on neuroendocrine tumors to patients, caregivers and physicians.
(See Story from BioSpace.com) (09/25/2006)



Sirtex Medical Names U.S. CEO Of Sales And Marketing Operations
LAKE FOREST, Ill.--(BUSINESS WIRE)--July 6, 2006--Sirtex Medical Inc., a leading developer of targeted and innovative cancer therapies, is pleased to welcome Nat Geissel as its U.S. CEO of sales and marketing operations. Sirtex manufactures SIR-Spheres® microspheres, the only FDA-approved microsphere treatment for advanced colorectal cancer that has metastasized to the liver. The company's U.S. headquarters are based in Lake Forest, Ill.
(See Story from BioSpace.com) (07/06/2006)



Landmark Study Evaluates Sirtex SIR-Spheres(R) Microspheres In Patients With Metastatic Liver Cancer
LAKE FOREST, Ill.--(BUSINESS WIRE)--May 15, 2006--A new study, published in the June issue of the International Journal of Radiation Oncology Biology Physics, examines the use of Sirtex SIR-Spheres microspheres in patients with unresectable metastatic liver cancer. According to the study, the use of SIR-Spheres microspheres in patients with advanced liver disease resulted in a median survival of 10.5 months from treatment. Sirtex's SIR-Spheres microspheres are the only FDA-approved radioactive microspheres for treatment of metastatic liver tumors.
(See Story from BioSpace.com) (05/15/2006)



Sirtex Medical Presents SIR-Spheres(R) Microspheres Data At The American Brachytherapy Society 2006 Meeting
PHILADELPHIA--(BUSINESS WIRE)--May 9, 2006--New research on Sirtex's SIR-Spheres® microspheres will be presented at the 2006 American Brachytherapy Society's annual meeting held May 10-12 in Philadelphia. Dr. Andrew Kennedy, co-medical director of Wake Radiology Oncology Services in Cary, N.C., will discuss findings of two studies involving SIR-Spheres microspheres for treatment of advanced liver cancer. Dr. Kennedy's presentation marks the first time microspheres therapy has been featured at the ABS meeting. Sirtex's SIR-Spheres microspheres are the only FDA-approved microspheres therapy for metastatic liver cancer.



Sirtex Medical Announces Clinical Trial Evaluating The Use Of SIR-Spheres(R) Microspheres With Xeloda(R) For Metastatic Liver Cancer
PHILADELPHIA--(BUSINESS WIRE)--May 8, 2006--Sirtex, a leading developer of targeted and innovative cancer therapies, announces the launch of a clinical trial evaluating the use of SIR-Spheres® microspheres in combination with the oral chemotherapy Xeloda (capecitabine) for patients with advanced metastatic liver cancers. The trial will be conducted in Philadelphia at the Fox Chase Cancer Center, one of the country's leading cancer institutes. Sirtex's SIR-Spheres microspheres are the only FDA-approved radioactive microspheres for the treatment of metastatic liver tumors. Xeloda, manufactured by Roche Pharmaceuticals, is the only FDA-approved oral chemotherapy for metastatic breast cancer, and adjuvant and metastatic colorectal cancer.



SIRTeX Medical Release: Leading Oncology Physicians From United States And Europe To Meet In Boston June 11 And 12 To Learn About Important New Treatment For Liver Cancer
CHICAGO--(BUSINESS WIRE)--May 25, 2005-- Symposium to Focus on Infusion of Microspheres, Which Has Proven Effective at Treating Many Forms of Liver Cancer, Including Cancers Resistant to Chemotherapy. The Procedure Offers New Hope to Tens of Thousands Who Annually Develop Cancers in the Liver Dozens of leading specialists in new oncology treatments for cancer will meet in Boston June 11 and 12 to learn about a promising new procedure that has proven effective at treating unresectable (inoperable) liver cancer. Each year in the United States, an estimated 150,000 new patients will develop cancer in the liver, and 95 percent will die. Given these numbers, infusion of yttrium-90 microspheres -- the topic of the meeting in Boston -- has the potential to save tens of thousands of patients every year. Infusion of yttrium-90 microspheres, as this new procedure is best known, is the subject of "Liver Directed Radiotherapy with Microspheres: A Clinical Symposium," which will be held at the Omni Parker House Hotel in downtown Boston. The media is invited to attend to learn more.
(See Story from BioSpace.com) (05/25/2005)



SIRTeX Medical Release: Liver Cancer Expert Presents New Data On SIR-Spheres; Addresses International Medical Conference In Washington, D.C.

WASHINGTON, June 3 /PRNewswire/ -- One of the world's leading experts in the treatment of liver cancer presented new data on SIR-Spheres(R) this week at the Sixth World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA). Dr. Richard Stubbs of the Wakefield Gastroenterology Centre in Wellington, New Zealand, presented evidence that treatment with SIR- Spheres (C2616-Brachytherapy-Yttrium 90) -- a form of therapeutic radioactive implant used to treat liver cancer -- can reduce liver tumors in more than 90 percent of patients after a single treatment of SIR-Spheres.
(See Story from BioSpace.com) (06/03/2004)








--------------------------------------------------------------------------------


| BioPharm Insight | News | Career | Hotbeds | Companies | FREE Magazines |
| Investor | Start-Ups | Expert Search | Science Center | Events | Marketplace |
| Resources | Real Estate | Search | GenePool | Help | Home |






Spectroscopy
Pharma DD
LC*GC North America
Hundreds more titles...







--------------------------------------------------------------------------------

Advertising Opportunities On BioSpace
Sponsorship Opportunities On BioSpace
BioSpace Information
Post a Job on BioSpace
Post an Event on BioSpace
Post your News on BioSpace
Post a Company Profile on BioSpace

--------------------------------------------------------------------------------